Once-Daily Two-Drug Oral Regimen Doravirine and Islatravir Offers New Option for Simplified HIV-1 Management

The FDA’s recent approval of Merck’s IDVYNSO™, a once-daily combination of doravirine and islatravir, represents more than just another checkbox in HIV treatment evolution—it’s a tangible shift that could reshape daily routines for thousands managing their health right here in Chicago. Even as the headlines focus on the science of two-drug regimens and adherence benefits, the real story unfolds in neighborhood clinics, pharmacy counters, and living rooms across the South and West Sides, where access to simpler, more sustainable treatment options has long been a critical gap in care.

This approval arrives amid persistent challenges in HIV management, particularly in urban centers like Chicago where socioeconomic factors often complicate treatment consistency. Historically, multi-pill regimens have posed significant adherence hurdles, especially for individuals navigating demanding work schedules, housing instability, or complex caregiving responsibilities. The promise of a single daily pill combining doravirine—an established non-nucleoside reverse transcriptase inhibitor (NNRTI)—with islatravir, a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI), addresses a core pain point: reducing pill burden without compromising efficacy. For communities disproportionately affected by HIV, such as Black and Latino residents on Chicago’s South and West Sides, this simplification isn’t merely convenient; it’s a potential catalyst for improved viral suppression rates and long-term health outcomes.

Beyond the individual patient experience, the approval carries meaningful implications for Chicago’s healthcare infrastructure. Institutions like the Ruth M. Rothstein CORE Center at Cook County Health, a national leader in HIV care and research, stand to integrate this regimen into their treatment protocols, potentially streamlining workflows for clinicians and pharmacists alike. Similarly, outpatient pharmacies operated by Walgreens across the city—particularly those in communities like Englewood, Humboldt Park, and Albany Park—may observe shifts in how antiretroviral therapy is dispensed and counseled, reinforcing the growing role of pharmacists as frontline care coordinators. The Chicago Department of Public Health’s STI/HIV Division could similarly leverage this development in its ongoing efforts to expand access to low-barrier treatment options through its network of community health centers.

What makes this advancement particularly relevant to Chicagoans is its alignment with broader trends toward decentralized, patient-centered care. As telehealth visits and home-based monitoring grow more normalized post-pandemic, a once-daily oral regimen fits seamlessly into models where patients manage more aspects of their care independently, yet remain connected to providers through digital platforms. This is especially pertinent in a city grappling with transportation barriers and clinic deserts on its far South Side, where reducing the frequency of pharmacy visits or lab monitoring could meaningfully improve retention in care. The regimen’s potential to reduce stigma—by minimizing the visibility of medication routines—resonates deeply in close-knit communities where privacy concerns often influence treatment decisions.

Of course, no medical advancement exists in a vacuum. While the FDA’s approval is based on robust clinical trial data showing non-inferiority to standard three-drug regimens, real-world effectiveness will depend on equitable access—a persistent challenge in Chicago. Factors like insurance coverage gaps, prior authorization delays, and pharmacy deserts in certain neighborhoods could initially limit uptake, underscoring the require for coordinated efforts between providers, insurers, and community organizations to ensure this innovation reaches those who need it most. Still, the introduction of IDVYNSO™ adds a valuable tool to Chicago’s arsenal in the ongoing fight to end the HIV epidemic—a goal the city has committed to through its Getting to Zero initiative.

Given my background in public health communications, if this trend impacts you or someone you care about in Chicago, here are the three types of local professionals you need to know about when navigating changes in HIV treatment options:

• HIV-Specialized Pharmacists: Look for professionals affiliated with accredited HIV clinical pharmacy programs (such as those offered through the American College of Clinical Pharmacy) who have demonstrable experience managing complex antiretroviral regimens. Prioritize those who offer medication therapy management (MTM) services and actively collaborate with local clinics like the CORE Center or Howard Brown Health to ensure seamless care coordination.
• Community Health Navigators: Seek individuals employed by reputable Chicago-based organizations (e.g., AIDS Foundation of Chicago, Taskforce Prevention and Community Services) who specialize in linking patients to treatment, insurance assistance, and support services. The best navigators possess deep cultural competency, particularly regarding the specific barriers faced by Black, Latino, and LGBTQ+ communities on the city’s South and West Sides, and can assist with everything from prior authorization appeals to transportation planning.
• Infectious Disease Physicians with HIV Expertise: Focus on providers board-certified in infectious disease who maintain active HIV medicine credentials through the HIV Medicine Association (HIVMA). Ideal candidates will have admitting privileges at major Chicago hospitals (like Rush University Medical Center or Northwestern Memorial Hospital) and a track record of participating in clinical research or quality improvement initiatives related to treatment simplification and adherence.

Ready to locate trusted professionals? Browse our complete directory of top-rated us experts in the Chicago area today.